
CLAIMS

What is claimed is:

~~1. A formulation comprising a capsule comprising at least one active pharmaceutical ingredient comprising a solubilized compound having the formula (I)~~



~~(I)~~

~~2. The formulation of claim 1, further comprising at least one solubilizer and optionally comprising at least one surfactant, and/or at least one stabilizer.~~

~~3. The formulation of claim 2, wherein the at least one stabilizer is included in the range from about 0.01 to about 1% w/w.~~

~~4. The formulation of claim 2 wherein the at least one active pharmaceutical ingredient is included in the range from about 0.1 to about 60% w/w, the at least one solubilizer is included in the range from about 1 to about 80% w/w, the at least one surfactant is included in the range from about 0 to about 60% w/w, and the at least one stabilizer is included in the range from about 0.01 to about 1% w/w.~~

~~5. The formulation of claim 2 wherein the at least one active pharmaceutical ingredient is included in the range from about 1 to about 40% w/w, the at least one solubilizer is included in the range from about 10 to about 80% w/w, the at least one surfactant is included in the range from about 5 to about 40% w/w, and the at least one stabilizer is included in the range from about 0.02 to about 0.5% w/w.~~

~~6. The formulation of claim 2 wherein the at least one active pharmaceutical ingredient is included in the range from about 1 to about 40% w/w, the at least one solubilizer is included in the range from about 5 to about 80% w/w, the at least one surfactant is included in the range from about 15 to about 40 % w/w, and the at least one stabilizer is included in the range from about 0.05 to about 0.2% w/w.~~

~~7. The formulation of claim 2 wherein the at least one solubilizer is comprised of medium-chain fatty acid triglycerides and a combination of medium-chain fatty acid mono- and diglycerides.~~


~~8. The formulation of claim 2 wherein the at least one solubilizer is polyoxyethylated glycerides.~~

~~9. The formulation of claim 2 wherein the at least one surfactant is polyoxyethylene sorbitan monooleate.~~

~~10. The formulation of claim 2 wherein the at least one stabilizer is butylated hydroxytoluene.~~

~~11~~1. A formulation comprising:

(a) at least one active pharmaceutical ingredient wherein the at least one active pharmaceutical ingredient comprises a compound of formula (I)



(I);

(b) at least one solubilizer selected from medium-chain fatty acid triglycerides, polyoxyethylated glycerides, a combination of medium-chain fatty acid mono- and

diglycerides, and combinations thereof;

(c) at least one surfactant which is polyoxyethylene sorbitan monooleate; and

(d) at least one stabilizer which is butylated hydroxytoluene.

~~12~~2. The formulation of claim ~~11~~1 wherein the at least one active pharmaceutical ingredient is included in the range from about 1 to about 40% w/w.

~~13~~3. The formulation of claim ~~11~~1 wherein the at least one stabilizer is included in the range from about 0.05 to about 0.2% w/w.

~~14~~4. The formulation of claim ~~11~~1 wherein the at least one solubilizer is medium-chain fatty acid triglycerides and a combination of medium-chain fatty acid mono- and diglycerides.

~~15~~5. The formulation of claim ~~14~~4 wherein the at least one solubilizer is included in the range from about 10 to about 80% w/w.


~~16~~6. The formulation of claim ~~15~~5 wherein the at least one surfactant is included in the range from about 15 to about 40% w/w.

~~17~~7. The formulation of claim ~~11~~1 wherein the at least one solubilizer is polyoxyethylated glycerides.

~~18~~8. The formulation of claim ~~17~~7 wherein the at least one solubilizer is included in the range from about 1 to about 80% w/w.

~~19~~9. The formulation of claim ~~17~~7 wherein the at least one surfactant is included in the range from about 1 to about 40% w/w.

~~20. A formulation comprising a capsule comprising at least one active pharmaceutical ingredient comprising a solubilized compound having the formula (I)~~



(I),

that is stable for at least six months at 40 °C and 75% relative humidity.

21. The formulation of claim 20, wherein the at least one active pharmaceutical ingredient has at least about 98% potency retention.

22. The formulation of claim 20, wherein the formulation has less than 10% total degradants.

23. The formulation of claim 20, wherein the formulation has less than 5% total degradants.

24. The formulation of claim 20, wherein the formulation has less than 2% total degradants.

25. The formulation of claim 20, wherein the formulation has less than 1% total degradants.


26. The formulation of claim 20, wherein the formulation has less than 0.5% total degradants.

27. The formulation of claim 20, wherein the formulation comprises at least one stabilizer in an amount from about 0.01 to about 1.0% w/w.

~~28. The formulation of claim 27, wherein the at least one stabilizer is selected from butylated hydroxytoluene, butylated hydroxyanisole, Vitamin E, propyl gallate, ascorbic acid, and tert-butylhydroquinone.~~

~~29. The formulation of claim 28, wherein the at least one stabilizer comprises butylated hydroxytoluene.~~

~~30~~10. ~~A method of administering a formulation comprising orally administering to a fasted or fed mammalian subject a~~ The use of a formulation comprising Compound (I) having the formula:



(I),

in the manufacture of a drug orally administered to a fasted or fed mammalian subject to provide a total blood plasma concentration profile of Compound (I), as measured by AUC at 24 hours after an initial dose of the composition, that is at least greater than about 50% of the total blood plasma concentration as measured by AUC at 24 hours of an initial dose of an orally administered solution comprising Compound (I).

~~31~~11. The ~~method~~ use of claim ~~30~~10, wherein the AUC is at least greater than about 60% of the AUC at 24 hours of the solution when orally administered regardless if the subject is fasted or fed.

~~32~~12. The ~~method~~ use of claim ~~30~~10, wherein the AUC is at least greater than about 70% of the AUC at 24 hours of the solution when orally administered regardless if the subject is fasted or fed.


~~33~~13. The ~~method~~use ~~of~~ claim ~~30~~10, wherein the AUC is at least greater than about 80% of the AUC at 24 hours of the solution when orally administered regardless if the subject is fasted or fed.

~~34~~14. The use ~~method~~ of claim ~~30~~10, wherein the AUC is at least greater than about 90% of the AUC at 24 hours of the solution when orally administered regardless if the subject is fasted or fed.

~~35~~15. The use ~~method~~ of claim ~~30~~10, wherein the formulation is in a form of a capsule.

~~36~~16. The ~~method~~ use of claim ~~30~~10, wherein the formulation is in a form of a solubilized capsule.

~~37~~17. ~~A method of administering a formulation comprising orally administering to a fasted mammalian subject the~~ The use of a composition comprising Compound (I) having the formula:



(I),

in the manufacture of a drug orally administered to a fasted mammalian subject to provide a blood plasma concentration profile after an initial dose of the composition with a Cmax of Compound (I) after an initial dose of the composition that is at least greater than about 40% of the Cmax of an orally administered solution comprising Compound (I).

~~38~~18. The ~~method~~ use of claim ~~37~~17, wherein the Cmax of the composition is at least or greater than about 50% of the Cmax of an orally administered solution.

~~39~~19. The ~~method~~ use of claim ~~37~~17, wherein the Cmax of the composition is at least or greater than about 60% of the Cmax of an orally administered solution.

~~40~~20. The ~~method~~ use of claim ~~37~~17, wherein the Tmax is at least about 3 hours.

~~41~~21. The ~~method~~ use of claim ~~37~~17, wherein the formulation is in a form of a capsule.


~~42~~22. The ~~method~~ use of claim ~~37~~17, wherein the formulation is in a form of a solubilized capsule.

~~43~~23. ~~A method of administering~~ The use of an oral solid dosage composition comprising ~~orally administering to a fasted mammalian subject the composition comprising~~ at least one poorly soluble active pharmaceutical ingredient in the manufacture of a drug orally administered to a fasted mammalian subject to provide a total blood plasma concentration profile as measured by AUC at 24 hours after an initial dose of the composition that is at least greater than about 50% of the total blood plasma concentration as measured by AUC at 24 hours of an initial dose of an orally administered solution comprising the at least one active pharmaceutical ingredient.

~~44~~24. The ~~method~~ use of claim ~~43~~23, wherein the active pharmaceutical ingredient exhibits a significant food effect.

~~45~~25. The ~~method~~ use of claim ~~43~~23, wherein the at least one active pharmaceutical ingredient is included in the range from about 0.1 to about 60% w/w.

~~46~~26. ~~A method of administering~~ The use of a formulation comprising ~~orally administering to a fasted mammalian subject the formulation comprising~~ Compound (I) having the formula



(I),

in the manufacture of a drug orally administered to a fasted mammalian subject, and the formulation has a fed to fasted ratio lower than at least about 2.

~~47~~27. The ~~method~~ use of claim ~~46~~26, wherein the fed to fasted ratio is less than about 1.5.

~~48~~28. The ~~method~~ use of claim ~~46~~26, wherein the fed to fasted ratio is less than about 1.0.

~~49~~29. The ~~method~~ use of claim ~~46~~26, wherein the fed to fasted ratio is less than about 0.75.

~~50~~30. The ~~method~~ use of claim ~~46~~26, wherein the formulation is in a form of a capsule.


~~51~~31. The ~~method~~ use of claim ~~46~~26, wherein the formulation is in a form of a solubilized capsule.

~~52. Use of a therapeutically effective amount of the formulation of claim 1 in the manufacture of a medicament for treating an HCV infection.~~

~~53~~32. Use of a therapeutically effective amount of the formulation of claim ~~1~~1 in the manufacture of a medicament for treating an HCV infection.

~~54. Use of a formulation comprising a capsule comprising at least one active pharmaceutical ingredient comprising a solubilized compound having the~~

formula (I)




(I),

wherein the total dose of the compound of formula (I) administered to the subject is about 200 mg a day, in the manufacture of a medicament for treating an HCV infection.

55. The use of claim 54 wherein the compound of formula (I) is administered to the subject in doses of 100 mg two times a day.


56. Use of a formulation comprising a capsule comprising at least one active pharmaceutical ingredient comprising a solubilized compound having the formula (I)



(I),

wherein the total dose of the compound of formula (I) administered to the subject is about 150 mg a day, in the manufacture of a medicament for treating an HCV infection.


57. A Use of a formulation comprising a capsule comprising at least one active pharmaceutical ingredient comprising a solubilized compound having the formula (I)



(I),

wherein the total dose of the compound of formula (I) administered to the subject is about 100 mg a day, in the manufacture of a medicament for treating an HCV infection.

58. Use of a formulation comprising a capsule comprising at least one active pharmaceutical ingredient comprising a solubilized compound having the formula (I)



(I),

wherein the total dose of the compound of formula (I) administered to the subject is about 50 mg a day, in the manufacture of a medicament for treating an HCV infection.